226 related articles for article (PubMed ID: 17371942)
1. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Bonomini S; Crugnola M; Mancini C; Martella E; Ferrari L; Tabilio A; Rizzoli V
Blood; 2007 Jul; 110(1):334-8. PubMed ID: 17371942
[TBL] [Abstract][Full Text] [Related]
2. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
[TBL] [Abstract][Full Text] [Related]
4. Bone building with bortezomib.
Roodman GD
J Clin Invest; 2008 Feb; 118(2):462-4. PubMed ID: 18219395
[TBL] [Abstract][Full Text] [Related]
5. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Heider U; Kaiser M; Müller C; Jakob C; Zavrski I; Schulz CO; Fleissner C; Hecht M; Sezer O
Eur J Haematol; 2006 Sep; 77(3):233-8. PubMed ID: 16923110
[TBL] [Abstract][Full Text] [Related]
7. Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib.
Uyama M; Sato MM; Kawanami M; Tamura M
Genes Cells; 2012 Jul; 17(7):548-58. PubMed ID: 22702336
[TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
Qiang YW; Hu B; Chen Y; Zhong Y; Shi B; Barlogie B; Shaughnessy JD
Blood; 2009 Apr; 113(18):4319-30. PubMed ID: 19196662
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.
Oyajobi BO; Garrett IR; Gupta A; Flores A; Esparza J; Muñoz S; Zhao M; Mundy GR
Br J Haematol; 2007 Nov; 139(3):434-8. PubMed ID: 17910634
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
Lund T; Søe K; Abildgaard N; Garnero P; Pedersen PT; Ormstrup T; Delaissé JM; Plesner T
Eur J Haematol; 2010 Oct; 85(4):290-9. PubMed ID: 20528908
[TBL] [Abstract][Full Text] [Related]
12. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
13. [Bortezomib depresses osteoblast apoptosis induced by mouse myeloma cells].
Zhao H; Bai QX; Huang GS; Yang LJ; Yue P; Zhang XY; Wang L; Fan LN; Zhu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1186-91. PubMed ID: 21129258
[TBL] [Abstract][Full Text] [Related]
14. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.
Giuliani N; Colla S; Morandi F; Lazzaretti M; Sala R; Bonomini S; Grano M; Colucci S; Svaldi M; Rizzoli V
Blood; 2005 Oct; 106(7):2472-83. PubMed ID: 15933061
[TBL] [Abstract][Full Text] [Related]
15. Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
Lee SE; Min CK; Yahng SA; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Eur J Haematol; 2011 Jan; 86(1):83-6. PubMed ID: 20946110
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
Mukherjee S; Raje N; Schoonmaker JA; Liu JC; Hideshima T; Wein MN; Jones DC; Vallet S; Bouxsein ML; Pozzi S; Chhetri S; Seo YD; Aronson JP; Patel C; Fulciniti M; Purton LE; Glimcher LH; Lian JB; Stein G; Anderson KC; Scadden DT
J Clin Invest; 2008 Feb; 118(2):491-504. PubMed ID: 18219387
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
Terpos E
Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
[No Abstract] [Full Text] [Related]
18. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues.
Sanvoranart T; Supokawej A; Kheolamai P; U-Pratya Y; Klincumhom N; Manochantr S; Wattanapanitch M; Issaragrisil S
Biochem Biophys Res Commun; 2014 May; 447(4):580-5. PubMed ID: 24747566
[TBL] [Abstract][Full Text] [Related]
20. Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Edwards CM; Lwin ST; Fowler JA; Oyajobi BO; Zhuang J; Bates AL; Mundy GR
Am J Hematol; 2009 May; 84(5):268-72. PubMed ID: 19296472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]